111 related articles for article (PubMed ID: 35383575)
1. Changes in Survival Outcomes of Patients With Neuroendocrine Neoplasms Over the Past 15 Years: A Real-World Study.
Abdel-Rahman O; Pham TM; Pokhrel A; Ruether D; Sawyer MB
Am J Clin Oncol; 2022 May; 45(5):208-214. PubMed ID: 35383575
[TBL] [Abstract][Full Text] [Related]
2. Impact of baseline body mass index on the outcomes of patients with neuroendocrine neoplasms.
Abdel-Rahman O; Ghosh S; Morrish D
J Endocrinol Invest; 2022 Sep; 45(9):1683-1688. PubMed ID: 35606667
[TBL] [Abstract][Full Text] [Related]
3. A Real-World, Population-Based Study for the Incidence and Outcomes of Neuroendocrine Neoplasms of Unknown Primary.
Abdel-Rahman O
Neuroendocrinology; 2021; 111(9):876-882. PubMed ID: 32980845
[TBL] [Abstract][Full Text] [Related]
4. A Real-World Study of the Incidence and Outcomes of Early-Onset Well-differentiated Neuroendocrine Neoplasms.
Abdel-Rahman O; Ghosh S
Am J Clin Oncol; 2022 Aug; 45(8):338-343. PubMed ID: 35696696
[TBL] [Abstract][Full Text] [Related]
5. Patterns of emergency department visits before diagnosis with digestive neuroendocrine neoplasms.
Abdel-Rahman O; Ghosh S
Int J Colorectal Dis; 2023 May; 38(1):148. PubMed ID: 37253995
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of Ramucirumab Plus Paclitaxel Among Patients With Previously Treated Metastatic Gastric/Lower Esophageal Cancer: A Real-world Study.
Abdel-Rahman O; Mulder K; Easaw J
Am J Clin Oncol; 2021 Apr; 44(4):158-161. PubMed ID: 33625121
[TBL] [Abstract][Full Text] [Related]
7. A Real-World, Population-Based Study for the Incidence and Outcomes of Neuroendocrine Neoplasms of Nondigestive, Nonpulmonary Primary.
Abdel-Rahman O; Ghosh S
Pancreas; 2022 Aug; 51(7):769-773. PubMed ID: 36395402
[TBL] [Abstract][Full Text] [Related]
8. Survival in Mesenchymal Chondrosarcoma Varies Based on Age and Tumor Location: A Survival Analysis of the SEER Database.
Schneiderman BA; Kliethermes SA; Nystrom LM
Clin Orthop Relat Res; 2017 Mar; 475(3):799-805. PubMed ID: 26975384
[TBL] [Abstract][Full Text] [Related]
9. Impact of Duration of Neoadjuvant Radiation on Rectal Cancer Survival: A Real World Multi-center Retrospective Cohort Study.
Abdel-Rahman O; Kumar A; Kennecke HF; Speers CH; Cheung WY
Clin Colorectal Cancer; 2018 Mar; 17(1):e21-e28. PubMed ID: 28709877
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of non-metastatic poorly differentiated gastroenteropancreatic neuroendocrine neoplasms treated with surgery: a real-world population-based study.
Abdel-Rahman O; Rahbari N; Reissfelder C; Oweira H
Int J Colorectal Dis; 2021 May; 36(5):941-947. PubMed ID: 33145607
[TBL] [Abstract][Full Text] [Related]
11. Impact of cytoreductive surgery on outcomes of metastatic appendiceal carcinoma: a real-world, population-based study.
Abdel-Rahman O
J Comp Eff Res; 2020 Apr; 9(6):431-439. PubMed ID: 32253936
[No Abstract] [Full Text] [Related]
12. Clinicopathologic characteristics and prognosis of gastroenteropancreatic neuroendocrine neoplasms: a multicenter study in South China.
Fang C; Wang W; Zhang Y; Feng X; Sun J; Zeng Y; Chen Y; Li Y; Chen M; Zhou Z; Chen J
Chin J Cancer; 2017 Jun; 36(1):51. PubMed ID: 28637502
[TBL] [Abstract][Full Text] [Related]
13. Tumor Macroscopic Morphology Is an Important Prognostic Factor in Predicting Chemotherapeutic Efficacy and Clinical Outcomes of Patients With Colorectal Neuroendocrine Neoplasms, One Multicenter Retrospective Cohort Study.
Wang Z; An K; Li R; Liu Q
Front Endocrinol (Lausanne); 2021; 12():801741. PubMed ID: 34987482
[TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of preoperative anemia on upper tract urothelial carcinoma.
Tan P; Xie N; Liao H; Zou L; Xu H; Yang L; Liu L; Wei Q
Medicine (Baltimore); 2018 Sep; 97(37):e12300. PubMed ID: 30212968
[TBL] [Abstract][Full Text] [Related]
15. Epidemiological trends and novel prognostic evaluation approaches of patients with stage II-IV colorectal neuroendocrine neoplasms: A population-based study with external validation.
Zhao F; Huang L; Wang Z; Wei F; Xiao T; Liu Q
Front Endocrinol (Lausanne); 2023; 14():1061187. PubMed ID: 36817582
[TBL] [Abstract][Full Text] [Related]
16. Impact of Time From Diagnosis to Treatment Start on the Outcomes of Patients With Nonmetastatic Anal Squamous Cell Carcinoma.
Abdel-Rahman O; Ghosh S
Am J Clin Oncol; 2023 Jan; 46(1):31-35. PubMed ID: 36453694
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin-Based versus Carboplatin-Based Chemotherapy for Extrapulmonary Neuroendocrine Carcinomas: A Real-World Study.
Abdel-Rahman O; Koski SL
Neuroendocrinology; 2022; 112(8):777-783. PubMed ID: 34649258
[TBL] [Abstract][Full Text] [Related]
18. Sex-based differences in the outcomes of patients with lung carcinoids.
Abdel-Rahman O; Ghosh S; Fazio N
J Comp Eff Res; 2022 May; 11(7):523-531. PubMed ID: 35388711
[No Abstract] [Full Text] [Related]
19. Prognostic impact of tumour burden in stage IV neuroendocrine neoplasia: A comparison between pancreatic and gastrointestinal localizations.
Panzuto F; Pusceddu S; Faggiano A; Rinzivillo M; Brighi N; Prinzi N; Riccardi F; Iannicelli E; Maggio I; Femia D; Tafuto S; Manuzzi L; Di Sarno A; Annibale B; de Braud F; Campana D;
Pancreatology; 2019 Dec; 19(8):1067-1073. PubMed ID: 31587962
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathologic Features and Survival Outcomes for Primary Renal Neuroendocrine Neoplasms.
Yi Z; Liu R; Hu J; He T; Wang Z; Li Y; Zu X
Clin Genitourin Cancer; 2021 Apr; 19(2):155-161. PubMed ID: 33288452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
